Dermira was a clinical-stage biopharmaceutical company that developed innovative therapies for patients with serious dermatologic diseases. The company's lead programs included treatments for hyperhidrosis (excessive sweating), atopic dermatitis, and acne. Dermira's flagship product was Qbrexza, an FDA-approved topical treatment for primary axillary hyperhidrosis. The company was acquired by Eli Lilly in 2020 for approximately $1.1 billion, expanding Lilly's dermatology portfolio.
Dermira has received investment from 1 venture capital firm.
Biopharmaceutical company focused on developing and commercializing novel therapeutics for dermatological conditions.
Dermira has received investment from Versant Ventures. These venture capital firms and investors provide both capital and strategic support.
Dermira has raised $400M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Dermira was founded in 2010 and is headquartered in Menlo Park, CA.
Dermira operates in the Biotech sector. Biopharmaceutical company focused on developing and commercializing novel therapeutics for dermatological conditions.
